What is the clinical evidence from this study?

Study design: RCT. Population: Doxorubicin-induced chronic heart failure. Intervention: Shenlijia (SLJ) vs. Control, CHF alone, and CHF + captopril (3.8 mg/kg per day). Primary outcome: Cardiac function (left ventricular ejection fraction, hemodynamic index) and interstitial fibrosis.

What question did this study set out to answer?

To evaluate the protective effects and molecular mechanisms of the herbal compound Shenlijia against doxorubicin-induced chronic heart failure.

July 16, 2021Evidence-based Complementary and Alternative MedicineOpen Access

Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis

View Full Paper

Ask AI

Bookmark

Key result

Shenlijia improves LVEF and inhibits interstitial fibrosis in rats with doxorubicin-induced heart failure.

Why the study?

Clinical application of doxorubicin is restricted by cardiotoxic side effects causing heart failure, and chemical agents for preventing doxorubicin-induced cardiotoxicity remain limited.

Does Shenlijia improve cardiac function and inhibit cardiac fibrosis in a rat model of doxorubicin-induced chronic heart failure?

Key Points

To evaluate the protective effects and molecular mechanisms of the herbal compound Shenlijia against doxorubicin-induced chronic heart failure.
Chronic heart failure was induced in rats via intraperitoneal doxorubicin injections over six weeks at a cumulative dose of 15 mg/kg.
Rats were randomly assigned to control, heart failure model, Shenlijia (3.0 g/kg per day), or captopril (3.8 mg/kg per day) groups and treated for four weeks.
Heart function was assessed using echocardiography and hemodynamics, while protein chips, immunohistochemistry, and western blots evaluated differential protein expression.
Shenlijia significantly improved cardiac function by increasing left ventricular ejection fraction and enhancing hemodynamic indexes compared to untreated heart failure models.
Shenlijia treatment suppressed myocardial interstitial fibrosis and preserved cardiac ultrastructure.
Protein analysis demonstrated that Shenlijia upregulated protective factors including TIMP-1/2/3 and downregulated MMP-13 expression.

Study Design

Type

RCT

Randomization

Randomized

Structured PICO

Does Shenlijia improve cardiac function and inhibit cardiac fibrosis in a rat model of doxorubicin-induced chronic heart failure?

Population

Rat model of doxorubicin (DOX)-induced chronic heart failure (induced by intraperitoneal injection of DOX for six weeks with a cumulative dose of 15 mg/kg)

Intervention

Shenlijia (SLJ) 3.0 g/kg per day for four weeks

Comparator

Control group, untreated CHF group, and CHF + captopril (3.8 mg/kg per day) group

Outcome

Cardiac function evaluated by echocardiography (left ventricular ejection fraction) and hemodynamic parameters, and interstitial fibrosissurrogate

Shenlijia, a traditional Chinese medicine compound, improves cardiac function and attenuates myocardial fibrosis in a rat model of doxorubicin-induced chronic heart failure.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Hypothesis-generating for Shenlijia in doxorubicin cardiotoxicity; leaves open translation to clinical practice.

Cite This Study

Sun et al. (2021) conducted an RCT in Doxorubicin-induced chronic heart failure. Shenlijia (SLJ) vs. Control, CHF alone, and CHF + captopril (3.8 mg/kg per day) was evaluated on Cardiac function (left ventricular ejection fraction, hemodynamic index) and interstitial fibrosis. Shenlijia treatment significantly improved cardiac function by increasing left ventricular ejection fraction and inhibiting interstitial fibrosis in rats with doxorubicin-induced chronic heart failure.

synapsesocial.com/papers/6a0f140625c30b2cc7fa16d9 https://doi.org/10.1155/2021/6659676

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Topics

Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider